Supplementary Table 1. Descriptive statistics of biochemistry at the baseline when Acamprosate® was initiated

Predictor	Reference range	Mean (SD)	*p*-value
ALT	F: ≤ 34 IU/L	45 (2.9)	0.125
	M: ≤ 45 IU/L	57 (3.4)	
AST	F: 6-34 IU/L	48 (1.2)	0.634
	M: 8-40 IU/L	57 (3.5)	
GGT	F: 5-55 IU/L	78 (6.5)	0.769
	M: 15-85 IU/L	97 (2.4)	

ALT=ALanine aminotransferase; AST=ASpartate aminotransferase; γGT=Gamma-Glutamyl Transferase; SD= Standard Deviation; *p*= <0.05

Supplementary Table 2. Characteristics of individuals who died within 1 year of starting Acamprosate®.

	Total number and characteristics of individuals prescribed Acamprosate®	Individuals prescribed Acamprosate® and died within one year of the study
Number	3319	252
Mean Age (SD)	48.41 (11.8)	49.93 (12.1)
Males	2047 (61.0%)	179 (71.0%)
Females	1272 (39.0%)	72 (28.6%)
SIMD **1** **2** **3** **4** **5**	529 (16.0%) 471 (14.0%) 430 (12.6%) 374 (10.6%) 237 (8.0%) 1176 (35.5%)	88 (34.9%) 65 (25.8%) 41 (16.3%) 23 (11.6%) 28 (6.0%)
Adherence **Low** **Good**	2732 (87.0%) 587 (13.0%)	217 (86.2%) 35 (13.8%)
Alcohol **Direct** **Not Direct**	198 (31.0%) 323 (69.0%)	101 (40.8%) 151 (59.2%)

SD= Standard Deviation; SUIMD= Scottish Index of Multiple Deprivation

Supplementary Table 3. Multivariate association between covariates and all cause mortality.

Predictor	HR	95% CI	*p*-value
Age	1.15	1.05-1.27	***<0.001***
Sex			0.001
M	0.082	0.013-0.53	0.027
F	0.104	0.02-0.67	0.046
SIMD	1.125	1.02-1.24	<0.05
Low Adherence	1.2	1.03-1.4	***<0.001***
Due to Alcohol	0.99	0.86-1.2	0.957
Number of other medications			
0	1.0		
1-2	0.75	0.46-1.23	n.s.
3-5	0.56	0.22-1.22	n.s.
6+	0.44	0.16-1.18	n.s.

n.s.= not significant; M=Male; F=Female; SIMD= Scottish Index of Multiple Deprivation
HR=Hazard Ratio; CI= Confidence Interval